Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation

Leukemia
R RosatoS Grant

Abstract

Interactions between the cyclin-dependent kinase inhibitor flavopiridol (FP) and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL/Apo2L), were examined in human leukemia cells (U937 and Jurkat). Coexposure of cells to marginally toxic concentrations of TRAIL and FP (24 h) synergistically increased mitochondrial injury (eg, cytochrome c, AIF, Smac/DIABLO release), cytoplasmic depletion of Bax, activation of Bid as well as caspase-8 and -3, PARP cleavage, and apoptosis. Coadministration of TRAIL markedly increased FP-induced apoptosis in leukemic cells ectopically expressing Bcl-2, Bcl-x(L), or a phosphorylation loop-deleted form of Bcl-2 (DeltaBcl-2), whereas lethality was substantially attenuated in cells ectopically expressing CrmA, dominant-negative-FADD, or dominant-negative-caspase-8. TRAIL/FP induced no discernible changes in FLIP, DR4, DR5, Mcl-1, or survivin expression, modest declines in levels of DcR2 and c-IAP, but resulted in the marked transcriptional downregulation of XIAP. Moreover, cells stably expressing an XIAP-antisense construct exhibited a pronounced increase in TRAIL sensitivity comparable to degrees of apoptosis achieved with TRAIL/FP. Conversely, enforced XIAP expression significantly ...Continue Reading

References

Sep 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A M SenderowiczE A Sausville
May 10, 2000·Nature Medicine·G Kroemer, J C Reed
Jul 25, 2000·The Journal of Biological Chemistry·S H ChaoD H Price
Aug 10, 2000·The Journal of Biological Chemistry·R DattaD Kufe
Jun 30, 2001·The Journal of Biological Chemistry·S H Chao, D H Price
Jan 10, 2002·Genes & Development·Yibin DengXiangwei Wu
Jan 17, 2002·Leukemia Research·Igor SemenovSeth J Corey
Mar 5, 2002·Nature Medicine·Wilfried Roth, John C Reed
Apr 12, 2002·Oncogene·Simone FuldaKlaus-Michael Debatin
Jan 18, 2003·Immunity·Mark J SmythHideo Yagita
Mar 26, 2003·Cell Death and Differentiation·S B Bratton, G M Cohen
Apr 30, 2003·Current Treatment Options in Oncology·Aaron D SchimmerJohn C Reed

❮ Previous
Next ❯

Citations

Dec 26, 2006·Cancer Chemotherapy and Pharmacology·Tamer E FandyRakesh K Srivastava
May 30, 2008·Cancer Chemotherapy and Pharmacology·Cornel J PhillipVarsha Gandhi
Oct 30, 2008·Journal of Medicinal Chemistry·Jui-Wen HuangMaurizio Pellecchia
May 7, 2008·Cell Research·Gustavo Ortiz-FerrónAbelardo López-Rivas
Aug 25, 2005·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Maoxin WuDavid E Burstein
Sep 25, 2008·Nature Reviews. Cancer·Ricky W JohnstoneMark J Smyth
Feb 3, 2007·Nature Reviews. Drug Discovery·Ching-Hon Pui, Sima Jeha
May 29, 2010·Cellular and Molecular Life Sciences : CMLS·Guillaume JacqueminOlivier Micheau
May 8, 2013·Expert Opinion on Investigational Drugs·Prithviraj BoseSteven Grant
Jul 14, 2010·Best Practice & Research. Clinical Haematology·Rong Chen, William Plunkett
Dec 29, 2009·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·J H StegehuisF A E Kruyt
Dec 23, 2008·Seminars in Hematology·Sima Jeha
May 8, 2014·Chemical Biology & Drug Design·Radek JordaVladimír Kryštof
Aug 9, 2005·Expert Opinion on Therapeutic Targets·Roberto R Rosato, Steven Grant
Jan 26, 2011·Cancer Biology & Therapy·Hope M AmmDonald J Buchsbaum
Aug 26, 2014·In Vitro Cellular & Developmental Biology. Animal·Anima Tripathi, Shail K Chaube
Apr 11, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Geoffrey I Shapiro
Dec 1, 2018·Journal of Cellular Physiology·Raedeh SaraeiAli Hassanzadeh
Jan 24, 2007·The Journal of Biological Chemistry·Reem BerroFatah Kashanchi
Dec 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Judith E KarpKenneth S Bauer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis